To the Editor The article by Yu et al1 is fascinating and important. They describe the hazard rates for distant recurrence in the 25-year period following a diagnosis of estrogen receptor–positive breast cancer. Patients were subdivided into whether they received tamoxifen or no endocrine therapy (randomly assigned) and if they had a luminal A or luminal B tumor subtypes. The benefit of tamoxifen in 25-year distant recurrence–free survival was substantial in both groups (luminal A subtype: 70% [95% CI, 62%-79%] for untreated patients vs 87% [95% CI, 82%-93%] for treated patients; P < .001; luminal B subtype: 54% [95% CI, 42%-70%] for untreated patients vs 67% [95% CI, 56%-82%] for treated patients; P = .04). These data should encourage the use of tamoxifen when appropriate. They had a substantial follow-up time (25 years), which is necessary to fully appreciate the influence of any intervention in patients with low-risk breast cancer. Overall, 21.6% of the patients experienced a distant recurrence.1
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Narod SA, Giannakeas V, Sopik V. Late Recurrences After Estrogen Receptor–Positive Breast Cancer. JAMA Oncol. 2020;6(2):301–302. doi:10.1001/jamaoncol.2019.5579
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: